Xolair Pfs Injection, Solution
Product Images NDC 50242-215

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Xolair Pfs (NDC 50242-215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 1 (Xolair 01)

This is a medication dosage sheet indicating the dosages for different medications given at different times to a patient. The instructions provide details on the recommended doses for different medications to be administered either every 2 or 4 weeks using subcutaneous injections.*

FDA Label Image

Table 2 (Xolair 02)

This appears to be a table with information related to pre-treatment and dosing of a medication or therapy. The table indicates the body weight range of the subject and the recommended dosage based on their weight, given in mg. The frequency of dosage is also specified for each weight range, with some administered every 4 weeks and others every 2 weeks via subcutaneous injection. There is also a note about insufficient data to recommend a dose for a certain weight range.*

FDA Label Image

Table 3 (Xolair 03)

FDA Label Image

Figure 1 (Xolair 04)

FDA Label Image

Figure 2 (Xolair 05)

Mean weekly ltch scores for different treatment periods and follow-up periods are given in the text. The text also lists the four treatment groups with their respective participant numbers. The provided table displays the primary efficacy results. However, no additional information is given, making it difficult to interpret the study results.*

FDA Label Image

Image (Xolair 06)

This text provides instructions on the parts of a prefilled syringe, including a needle-shield, needle-shield wings, expiration date, and needle cap. It also advises on how to position the needle-shield before and after use.*

FDA Label Image

Image (Xolair 07)

The text appears to be a list of items related to the administration of Xolair, a drug that treats asthma and certain types of hives. The list includes a prefilled syringe of Xolair, sterile cotton, alcohol swabs or gauze for cleaning the injection site, sharps disposal for safe disposal of the needle, and a bandage container for post-injection care.*

FDA Label Image

Image (Xolair 08)

XOLAIR is a medication that comes in a 75 mg prefilled syringe. The rest of the text is not readable.*

FDA Label Image

Image (Xolair 09)

This appears to be a chart displaying the number of dose syringes needed for administering varying doses of a medication called "REN T". The medication appears to come in dosages of 75mg, 150mg, and 225mg (a combination of a blue syringe and a purple syringe), 300mg (two purple syringes), 375mg (one blue syringe and two purple syringes), 450mg (three purple syringes), 525mg (one blue syringe and three purple syringes), and 600mg (four purple syringes).*

FDA Label Image

Image (Xolair 10)

This text is a label indicating the expiration date of a product or document. It includes the abbreviation for the month in three letters and the four-digit year. It does not provide any specific information regarding a particular product or document.*

FDA Label Image

Image (Xolair 11)

FDA Label Image

Image (Xolair 12)

This appears to be a label or instruction related to a product. It includes a "Peel tab" which could be a removable seal or sticker, and an "Expiration Date" which is formatted as "MMM YYYY" (month and year). The purpose of this text is likely to indicate to the user when the product should no longer be used or consumed.*

FDA Label Image

Image (Xolair 13)

FDA Label Image

Image (Xolair 14)

FDA Label Image

Image (Xolair 15)

FDA Label Image

Image (Xolair 16)

FDA Label Image

Image (Xolair 17)

FDA Label Image

Image (Xolair 18)

FDA Label Image

Image (Xolair 19)

FDA Label Image

Image (Xolair 20)

FDA Label Image

Image (Xolair 21)

FDA Label Image

Principal Display Panel (150 mg Vial Carton)

This is a product description for Yolair, which contains omalizumab, and is supplied in a single-dose vial with a strength of 150 mg. It is intended for subcutaneous use and must be refrigerated but should not be frozen. The product is manufactured by a partnership between Genentech and Novartis, as evidenced by their logos on the label.*

FDA Label Image

Principal Display Panel (75 mg/0.5 mL Syringe Carton)

Xolair® (omalizumab) Injection is a medication available in a single-dose prefilled syringe with a concentration of 75mg/0.5ml for subcutaneous use. It is important to note that the needle cap may contain natural rubber latex which may cause allergic reactions in individuals sensitive to latex. Patients should be given a medication guide and should contact their healthcare provider with any questions. Xolair is manufactured by Novartis.*

FDA Label Image

Principal Display Panel (150 mg/mL Syringe Carton)

Xolair® is a medication used for subcutaneous injection that comes in a single-dose prefilled syringe containing 150 mg/m. The needle cap may contain natural rubber latex that may cause an allergic reaction in latex-sensitive individuals. Patients should be provided with a Medication Guide and contact their healthcare provider for questions. The medication may require more than one injection. Genentech and Novartis are the manufacturers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.